Beijing Daxiang Biotech Co., Ltd.
PrivateLast Round
Series B
Feb 13, 2026
Total Funding Raised
$42.27M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Beijing Daxiang Biotech Co., Ltd. operates in Healthcare & Life Sciences and is based in Beijing. Its latest recorded funding round was a Series B round in February 2026.
Beijing Daxiang Biotech Co., Ltd. is a biotechnology company that develops organ-on-a-chip and organoid technologies for drug discovery, disease modeling, and precision medicine.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Beijing Daxiang Biotech Co., Ltd. Comparables
Compare Beijing Daxiang Biotech Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Jiangsu Avatarget Biotechnology Co., Ltd. | 91% | |
| D1 Medical Technology | 89% | |
| Anhui Luohua Biotechnology Co., Ltd. | 89% |
For institutional investors. Book with your work email.
Beijing Daxiang Biotech Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 13, 2026 | ||||
| Pre Seed | Nov 14, 2022 | ||||
| Series A Extension | Jul 30, 2021 | ||||
| Series A | May 11, 2021 | ||||
| Angel | Sep 12, 2020 | ||||
Seed | Aug 1, 2019 |
For institutional investors. Book with your work email.
Beijing Daxiang Biotech Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Qiandao Fund | Pre Seed |
| MiraclePlus | Seed, Series A |
| CDH VGC | Series A Extension, Series A |
| Proxima Ventures Ltd. | Pre Seed |
| Jiuyo Capital Management | Angel, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 13, 2026
$14.5M round completed.
- Apr 9, 2025
Monthly visitors grew 128% MoM, reaching 162.
For institutional investors. Book with your work email.
Beijing Daxiang Biotech Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Beijing Daxiang Biotech Co., Ltd.'s valuation, stock price, and market status.
Is Beijing Daxiang Biotech Co., Ltd. a public or private company?
Beijing Daxiang Biotech Co., Ltd. is a private company.
What is the current stock price of Beijing Daxiang Biotech Co., Ltd.?
Beijing Daxiang Biotech Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Beijing Daxiang Biotech Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Beijing Daxiang Biotech Co., Ltd. worth (valuation)?
Valuation information for Beijing Daxiang Biotech Co., Ltd. is not publicly available.
Can I buy Beijing Daxiang Biotech Co., Ltd. stock?
Beijing Daxiang Biotech Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Beijing Daxiang Biotech Co., Ltd.'s last funding round?
Beijing Daxiang Biotech Co., Ltd.'s most recent funding round was Series B on February 13, 2026.
Who are the main investors in Beijing Daxiang Biotech Co., Ltd.?
Key investors in Beijing Daxiang Biotech Co., Ltd. include CDH VGC, Proxima Ventures Ltd..
Will Beijing Daxiang Biotech Co., Ltd. IPO soon?
No public IPO plans have been announced for Beijing Daxiang Biotech Co., Ltd..
How can I track Beijing Daxiang Biotech Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Beijing Daxiang Biotech Co., Ltd.'s shares on secondary markets.